Results 241 to 250 of about 5,005,447 (264)
Some of the next articles are maybe not open access.
Diffusion of Tranexamic Acid to the Joint
Acta Orthopaedica Scandinavica, 1976Tranexamic acid (Cyklokapron, Kabi, Stockholm) in a dose of 10 mg per kg body weight was given i.v. to 17 patients at various intervals before operation on the knee joint, in order to elucidate the diffusion of the drug to the joint fluid and the synovial membrane.
Olle Eriksson +2 more
openaire +3 more sources
Hospital Pharmacy, 2010
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
Dennis J. Cada +2 more
openaire +2 more sources
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
Dennis J. Cada +2 more
openaire +2 more sources
Journal of dermatological treatment (Print), 2020
Background Melasma is a common acquired disorder of pigmentation. Objective To compare the efficacy of oral tranexamic acid (TA) versus oral TA and Q-switched Nd: YAG laser (1064-nm wavelength) in the treatment of melasma.
N. Agamia +3 more
semanticscholar +1 more source
Background Melasma is a common acquired disorder of pigmentation. Objective To compare the efficacy of oral tranexamic acid (TA) versus oral TA and Q-switched Nd: YAG laser (1064-nm wavelength) in the treatment of melasma.
N. Agamia +3 more
semanticscholar +1 more source
Journal of Trauma and Acute Care Surgery, 2019
BACKGROUND Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death. However, the risk of venous thromboembolism (VTE) has been incompletely explored.
Sara P. Myers +6 more
semanticscholar +1 more source
BACKGROUND Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death. However, the risk of venous thromboembolism (VTE) has been incompletely explored.
Sara P. Myers +6 more
semanticscholar +1 more source
Journal of dermatological treatment (Print), 2020
Background Tranexamic acid is a promising drug for melasma treatment, but its topical formulation has limited efficacy. Its use as liposome based cream or in combination with other modalities might help to achieve better results.
M. Gamea, D. Kamal, A. Donia, D. Hegab
semanticscholar +1 more source
Background Tranexamic acid is a promising drug for melasma treatment, but its topical formulation has limited efficacy. Its use as liposome based cream or in combination with other modalities might help to achieve better results.
M. Gamea, D. Kamal, A. Donia, D. Hegab
semanticscholar +1 more source
Effect of Local Tranexamic Acid on Hemostasis in Rhytidectomy.
Facial Plastic Surgery & Aesthetic Medicine, 2020Importance: Hematoma is the most common complication in rhytidectomy. Tranexamic acid (TXA) is an antifibrinolytic that may be a useful tool to reduce intraoperative bleeding and postoperative hematoma risk.
R. Schroeder, P. Langsdon
semanticscholar +1 more source
Pharmacokinetics and bioavailability of tranexamic acid
European Journal of Clinical Pharmacology, 1981Tranexamic acid 1 g was given intravenously to three healthy volunteers. Plasma concentrations decayed in three monoexponential phases. Most elimination took place during the first eight hours, giving an apparent elimination half-life of approximately two hours. Plasma clearance ranged between 110-116 ml/min.
J. Vessman, M. Schannong, Å. Pilbrant
openaire +3 more sources
Clinical Pharmacology of Tranexamic Acid [PDF]
Scandinavian Journal of Gastroenterology, 1987 Tranexamic acid (AMCA) is a potent antifibrinolytic drug occurring in two isomeric forms; the antifibrinolytic potency resides in the transisomeric form. The main action of AMCA is blocking of the lysine-binding sites of the plasminogen molecule, which are of importance for the binding to fibrin.
openaire +2 more sources
Dosing of tranexamic acid in trauma
Current Opinion in AnaesthesiologyPurpose of review Tranexamic acid is routinely used as part of the management of traumatic bleeding. The dose recommendation in trauma was extrapolated from other clinical settings and the results of pragmatic randomized trials rather than pharmaco-kinetic and -dynamic evaluations.
Faraoni, David +1 more
openaire +3 more sources